Moreover, PDLIM2 nanotherapy prevents the induction of MDR1 and the expression of tumor-related genes and in particular cell survival genes, further sensitizing tumor cells to the cytotoxicity of chemotherapeutic drugs and immune cells including those recruited by chemotherapy and unleashed by PD-1 blockade. This evidence concerns the gene PDCD1 and neoplasm.